In brief: Prima, SciGen, Sonic
Thursday, 30 June, 2005
The executive director of the Austin Research Institute, Mark Hogarth, has resigned as a director of Prima Biomed (ASX:PRR). The company cited Hogarth's increased responsibilities at the ARI for his resignation.
SciGen (ASX:SIE) managing director and CEO Mark Compton will leave the company on August 5. While he will remain as CEO till then, he has resigned as a director, effective June 29. SciGen is searching for a new CEO who is likely to be based in Asia.
Former CEO and executive director of the Melbourne Pathology Group, Lou Panaccio has joined the board of Sonic Healthcare (ASX:SHL) as a non-executive director. He will also replace Colin Jackson as a member of the Audit Committee.
Noxopharm says paper reveals science behind its immune system platform
Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...
Neurosensing/neurostimulation implants session to be held on Monday
On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
